Cecilio Santander

ORCID: 0000-0001-5492-2535
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Eosinophilic Esophagitis
  • Esophageal and GI Pathology
  • Eosinophilic Disorders and Syndromes
  • Gastroesophageal reflux and treatments
  • Gastrointestinal disorders and treatments
  • Inflammatory Bowel Disease
  • Gastrointestinal motility and disorders
  • Microscopic Colitis
  • Helicobacter pylori-related gastroenterology studies
  • Pancreatitis Pathology and Treatment
  • Gastric Cancer Management and Outcomes
  • Dysphagia Assessment and Management
  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Surgical Treatments
  • Intestinal Malrotation and Obstruction Disorders
  • Colorectal Cancer Screening and Detection
  • Digestive system and related health
  • Gallbladder and Bile Duct Disorders
  • Diet and metabolism studies
  • Gastrointestinal Tumor Research and Treatment
  • Liver Disease Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Pediatric Hepatobiliary Diseases and Treatments
  • Clinical Nutrition and Gastroenterology
  • Gastrointestinal Bleeding Diagnosis and Treatment

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2025

Hospital Universitario de La Princesa
2016-2025

Universidad Autónoma de Madrid
2008-2025

Instituto de Salud Carlos III
2008-2024

Centro de Investigación Biomédica en Red
2020-2023

University of Arkansas for Medical Sciences
2020

The Wright Center for Graduate Medical Education
2020

Sociedad Española de Endoscopia Digestiva
2019

Sociedad Española de Patología Digestiva
2019

Universidad Centroccidental Lisandro Alvarado
2018

Alfredo J. Lucendo Stephan Miehlke Christoph Schlag Michael Vieth Ulrike von Arnim and 91 more Javier Molina‐Infante Dirk Hartmann Albert J. Bredenoord Constanza Ciriza de los Ríos Stefan Schubert Stefan Brückner Ahmed Madisch Jamal Hayat Jan Tack Stephen Attwood Ralph Müeller Roland Greinwald Alain Schoepfer Alex Straumann Jan Tack Tim Vanuytsel Hubert Louis Carmen Musala Stephan Miehlke Dorothea Frederking Monther Bajbouj Christoph Schlag Simon Nennstiel Stefan Brückner Renate Schmelz Schmelz Heimerl Anna-Magdalena Stephan Christiane Fibbe Niels Liedtke Jutta Keller Ulrich Rosien Sebastian Haag A Schneider Dirk Hartmann Christoph Schmöcker Hendrik Buchholz Frank Lammert Markus Casper Matthias Reichert Ahmed Madisch D. Sommer Hubert Mönnikes Miriam Stengel M. Schmidtmann Michaela Müller Alexander J. Eckardt Till Wehrmann Stefan Schubert Peter Armerding Wolf Peter Hofmann Thomas Liceni Ulrike von Arnim Arne Kandulski Jochen Weigt Norbert Börner A. Lutz-Vorderbrügge Jörg Albert Stefan Zeuzem Irina Blumenstein Kathrin Sprinzl Johannes Hausmann Arjan Bredenoord Arjan Bredenoord Marijn J. Warners Alfredo Lucendo Villarin Ángel Arias Maria Ángeles Tejero Bustos María Jesús Carrillo Ramos J.M. Gallardo Rocío Juárez Tosina Javier Molina‐Infante José Luis Zamorano Cecilio Santander Sergio Casabona Maria T. Perez Teresa Rodríguez Constanza Ciriza de los Ríos Fernando Canga Rodríguez‐Valcárcel Isabel Castel de Lucas Antonia Perelló Juan Mercè Barenys Carlos Casasnovas Isabel Pérez‐Martínez M. Eugenia Lauret Andrés Castaño García Esmeralda Rubio Alex Straumann Petr Hrúz Simon Brunner Jamal Hayat Andrew Poullis

Background & AimsSwallowed topical-acting corticosteroids are recommended as first-line therapy for eosinophilic esophagitis (EoE). Asthma medications not optimized esophageal delivery sometimes effective, although given off-label. We performed a randomized, placebo-controlled trial to assess the effectiveness and tolerability of budesonide orodispersible tablet (BOT), which allows drug be delivered esophagus in adults with active EoE.MethodsWe double-blind, parallel study 88 EoE Europe....

10.1053/j.gastro.2019.03.025 article EN cc-by-nc-nd Gastroenterology 2019-03-26

Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder. Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission. However, it not clear whether these drugs for long-term maintenance of remission.We performed double-blind trial to compare the efficacy and safety 2 dosages budesonide orodispersible tablet (BOT) vs placebo maintaining remission EoE. Maintenance was defined as absence clinical histologic relapse no premature withdrawal any reason....

10.1053/j.gastro.2020.07.039 article EN cc-by-nc-nd Gastroenterology 2020-07-25

This study sought to determine the prevalence of malnutrition in patients with inflammatory bowel disease, analyse dietary beliefs and behaviours these patients, their body composition, evaluate muscular strength identify factors associated patients.This was a prospective, multicentre study. Crohn's disease ulcerative colitis from 30 Spanish centres, outpatient clinics, were included. A questionnaire 11 items applied obtain data patients' behaviour beliefs. Patients who accepted evaluated...

10.1093/ecco-jcc/jjx102 article EN Journal of Crohn s and Colitis 2017-07-20

Abstract Background Esophagogastric junction outflow obstruction ( EGJOO ) is a newly described diagnostic entity growing in importance due to the use of high resolution manometry HRM ). There little knowledge regarding its incidence, etiopathogeny, long‐term evolution, and most suitable treatment. Our objective was increase awareness optimize management these patients. Methods We conducted historical (retrospective prospective) study patients diagnosed with using combined multichannel...

10.1111/nmo.12708 article EN Neurogastroenterology & Motility 2015-10-30

Although macrophages (Mϕ) maintain intestinal immune homoeostasis, there is not much available information about their subset composition, phenotype and function in the human setting. Human Mϕ (CD45+HLA-DR+CD14+CD64+) can be divided into subsets based on expression of CD11c, CCR2 CX3CR1. Monocyte-like cells identified as CD11chighCCR2+CX3CR1+ cells, a also shared by circulating CD14+ monocytes. On contrary, Mϕ-like tissue-resident counterparts display CD11c-CCR2-CX3CR1- phenotype. CD11chigh...

10.1038/s41385-018-0030-7 article EN publisher-specific-oa Mucosal Immunology 2018-05-03

Summary Background Proton pump inhibitors (PPIs) are the most commonly used first‐line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE still unknown. Aims To assess effectiveness of PPI real‐world practice. Methods This cross‐sectional study collected data on efficacy from multicentre CONNECT database. Clinical remission was defined as a decrease ≥50% dysphagia symptom score; histological peak eosinophil count below 15 eosinophils per...

10.1111/apt.15957 article EN Alimentary Pharmacology & Therapeutics 2020-07-17

Esophageal motility abnormalities, as measured by conventional manometry (CM), are non-specific in the majority of patients with eosinophilic esophagitis (EoE). Moreover, study CM is limited poor interobserver agreement. The aims present were: (i) to assess esophageal patterns EoE a topographic analysis high-resolution (HRM) data; and (ii) establish relationship between abnormalities symptoms EoE, such dysphagia bolus impaction.All adult diagnosed according histological criteria, controls...

10.1111/j.1440-1746.2011.06770.x article EN Journal of Gastroenterology and Hepatology 2011-05-17

Eosinophilic esophagitis (EoE) is a chronic non-IgE-mediated allergic disease of the esophagus. An unbiased proteomics approach was performed to investigate pathophysiological changes in esophageal epithelium. Additionally, an RNAseq-based transcriptomic analysis paired samples also carried out.Total proteins were purified from endoscopic biopsies cohort adult EoE patients (n = 25) and healthy esophagus controls 10). Differentially accumulated (DA) compared control tissues characterized...

10.1111/all.15779 article EN cc-by-nc-nd Allergy 2023-06-07

Abstract Background Poor adherence to clinical practice guidelines for eosinophilic esophagitis (EoE) has been described and the diagnostic delay of disease continues be unacceptable in many settings. Objective To analyze impact improved knowledge provided by successive international on reducing improving process European patients with EoE. Methods Cross‐sectional analysis EoE CONNECT registry based practice. Time periods defined publication dates four major sets over 10 years were...

10.1002/ueg2.12240 article EN United European Gastroenterology Journal 2022-05-16

Abstract Background A novel budesonide orodispersible tablet (BOT) has been proven effective in adult patients with active eosinophilic oesophagitis (EoE) a 6‐week placebo‐controlled trial (EOS‐1). Aims To report the efficacy of an open‐label induction treatment BOT large prospective cohort EoE within EOS‐2 study. Methods Patients clinico‐histological were treated 1 mg BID for 6 weeks. The primary endpoint was remission (≤2 points on numerical rating scales [0–10] each dysphagia and...

10.1002/ueg2.12220 article EN cc-by-nc-nd United European Gastroenterology Journal 2022-04-01

Abstract Purpose Eosinophilic esophagitis (EoE), a chronic immune-mediated progressive disease, causes dysphagia, food impaction, abdominal pain, vomiting, and heartburn. EoE requires long-term monitoring can affect quality of life owing to its symptoms associated emotional social burden. This study aimed understand patients’ experiences with EoE. Methods Semi-structured longitudinal interviews were conducted patients from MESSINA, phase 3 placebo-controlled trial evaluating benralizumab for...

10.1186/s41687-025-00836-x article EN cc-by Journal of Patient-Reported Outcomes 2025-01-08

Functional dyspepsia (FD) is a gut-brain axis disorder characterized by postprandial fullness, early satiety, bloating and/or epigastric pain, which are presumed to originate in the gastroduodenal tract. While international recommendations Rome IV consensus require endoscopy rule out an organic condition before establishing diagnosis of FD, guidelines recommend that, absence risk factors, patient management be initiated at primary care level Helicobacter pylori infection status, with...

10.17235/reed.2025.10572/2024 article EN publisher-specific-oa Revista Española de Enfermedades Digestivas 2025-01-01

High-resolution anorectal manometry (HR-ARM) is the gold standard for functional disorders' evaluation, despite being limited by its accessibility and complex data analysis. The London Protocol Classification were developed to standardize motility patterns classification. This proof-of-concept study aims develop validate an artificial intelligence model identification differentiation of disorders anal tone contractility in HR-ARM. A dataset 701 HR-ARM exams from a tertiary center, classified...

10.1038/s41598-024-83768-8 article EN cc-by-nc-nd Scientific Reports 2025-01-15

Abstract Background Capsule endoscopy (CE), is a minimally invasive diagnostic tool critical for evaluating small bowel conditions, particularly Crohn's disease. Detecting ulcers and erosions essential assessing disease activity, guiding treatment decisions, monitoring therapeutic responses. While CE revolutionized lesion detection, its manual interpretation time-consuming prone to variability. Artificial intelligence (AI) tools, including convolutional neural networks (CNNs), have emerged...

10.1093/ecco-jcc/jjae190.0128 article EN Journal of Crohn s and Colitis 2025-01-01

Abstract Background and aims Faecal incontinence (FI) rectal urgency (RU) are underestimated underdiagnosed in ulcerative colitis (UC) patients. Our primary aim is to evaluate the prevalence severity of FI and/or RU UC Secondary include investigating causes RU, identifying factors associated with describing anorectal function patients remission who report these symptoms. Methods This a prospective, multicentre study two parts. The first part an epidemiological analysis involving 667...

10.1093/ecco-jcc/jjae190.1603 article EN Journal of Crohn s and Colitis 2025-01-01

Abstract Background Limited literature is available on EoE disease duration and response to therapy. Dupilumab approved for in patients aged ≥12 years, weighing ≥40 kg, the EU, ≥1 year, ≥15 USA Canada. Aims To assess long-term efficacy of dupilumab with stratified by baseline duration. Methods In Part B LIBERTY TREET (NCT03633617), received 24 weeks 300 mg or placebo weekly (qw). Eligible who completed through 52 (Part C). Co-primary endpoints were proportion achieving peak esophageal...

10.1093/jcag/gwae059.140 article EN cc-by Journal of the Canadian Association of Gastroenterology 2025-02-01
Coming Soon ...